Reasons for reassignment of urate-lowering therapy from initial treatment.
| Reason | Febuxostat 80 mg, N = 649 n (%) | Febuxostat 120 mg, N = 292 n (%) | Allopurinol, N = 145 n (%) |
|---|---|---|---|
| Overall | 164 (25.2) | 91 (31.2) | 86 (59.3) |
| SUA > 6.0 mg/dl | 141 (21.7) | 22 (7.5) | 82 (56.6) |
| SUA < 3.0 mg/dl | 1 (0.2) | 41 (14.0) | 0 |
| Adverse event | 1 (0.2) | 7 (2.4) | 1 (0.7) |
| Other | 18 (2.8) | 20 (6.8) | 3 (2.1) |
| No reason provided | 3 (0.5) | 1 (0.3) | 0 |
SUA: serum uric acid.